Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for ˜85% of lung malignancies, which are the leading cause of cancer-related deaths worldwide. In 2011, the National Lung Cancer Screening Trial (NLST) demonstrated in subjects at high-risk that mortality can be reduced 20% by screening with low-dose CT (LDCT) [1]. The U.S. Preventive Services Task For ce recommends LDCT screening in individuals 55-80 years of age with ≥30 pack-year smoking history, current smokers or who have quit within the last 15 years (grade B evidence).

Source: Lung Cancer - June 16, 2019 Category: Cancer & Oncology Authors: Yariswamy Manjunath, Sathisha V. Upparahalli, Kanve N. Suvilesh, Diego M. Avella, Eric T. Kimchi, Kevin F. Staveley-O ’Carroll, Guangfu Li, Jussuf T. Kaifi Source Type: research